Nov 1997 - Present
I began my tenure with The Rogosin Institute at it's Xenia, Ohio laboratory, as a lab technician, first in its diabetes research project (Islet Isolation Laboratory), then in its cancer research laboratory. While most of Rogosin's operations are in New York City, these labs were investigating cell encapsulation technology for human medical use. In the cancer project I became the project manager and study director for pre-clinical trials of a product we called the "cancer macrobead". I began reporting directly to Barry Smith, M.D., Ph.D., now the President/Director of The Rogosin Institute. I was supervising a talented group of about seven other technicians. We developed this technology into a promising cancer therapy and submitted an Investigational New Drug (IND) application to the FDA in 2003. The application was ultimately approved and the product is currently in phase-2 human trials, after successfully completing phase-1 trials.
In 2003 Rogosin's cancer project was transitioning from a research phase to a production phase, and in the previous years I had the opportunity to work with a new Quality team to supervise the installation of a quality system into our operations. This was a huge endeavor and a valuable experience.
As we completed the transition to production in Xenia, much of the science and molecular biology of the project was shifting to the facilities in Manhattan, at Rockefeller University, and New York Presbyterian/Cornell Medical School. I was offered the opportunity to join the team there and given the flexibility to pursue my graduate education at Columbia University. While my graduate research interests were separate and did not involve Rogosin, I was able to help Rogosin to continue a research collaboration in the laboratory of Carlos Cordon-Cardo at Columbia, which we had begun in his lab at Memorial Sloan-Kettering Cancer Center.